MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 330091 | Name: Mangafodipir trisodium
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Mangafodipir, also known as MnDPDP, is a contrast agent delivered intravenously to enhance contrast in magnetic resonance imaging (MRI) of the liver, and has potential to serve as an adjunct for various chemotherapeutic agents and during coronary intervention. It has two parts, a paramagnetic manganese(II) ion and the fodipir (dipyridoxyl diphosphate, DPDP) chelating agent. When freed from the organic ligand, the manganese shortens the longitudinal relaxation time (T1) in an MRI scan. Normal liver tissue absorbs the manganese more than abnormal or cancerous tissue, which makes the normal tissue appear brighter in MRIs. This enhanced contrast allows lesions to be more easily identified. Mangafodipir was withdrawn from the US market in 2003 and the European market in 2012 for commercial reasons by the manufacturer.

Chemical Structure

Mangafodipir trisodium
Mangafodipir trisodium
CAS#140678-14-4 (sodium)

Theoretical Analysis

MedKoo Cat#: 330091

Name: Mangafodipir trisodium

CAS#: 140678-14-4 (sodium)

Chemical Formula: C22H27MnN4Na3O14P2

Exact Mass: 0.0000

Molecular Weight: 757.33

Elemental Analysis: C, 34.89; H, 3.59; Mn, 7.25; N, 7.40; Na, 9.11; O, 29.58; P, 8.18

Price and Availability

Size Price Availability Quantity
5mg USD 550.00 2 Weeks
10mg USD 950.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
155319-91-8 (free acid) 118248-94-5 (anion) 140678-14-4 (sodium) 118248-91-2 (Fodipir)
Synonym
Mangafodipir sodium; Manganese dipyridoxal diphosphate; Mangafodipir; mangafodipir trisodium; MnDPDP; S 095; Teslascan; Win 59010; Win-59010; Win59010;
IUPAC/Chemical Name
Manganate(6-), [[rel-[N(R),N′(R)]-N,N′-1,2-ethanediylbis[N-[[3-(hydroxy-κO)-2-methyl-5-[(phosphonooxy)methyl]-4-pyridinyl]methyl]glycinato-κN,κO]](8-)]-, sodium hydrogen (1:3:3), (OC-6-13)-
InChi Key
BENFPBJLMUIGGD-UHFFFAOYSA-I
InChi Code
InChI=1S/C22H32N4O14P2.Mn.3Na/c1-13-21(31)17(15(5-23-13)11-39-41(33,34)35)7-25(9-19(27)28)3-4-26(10-20(29)30)8-18-16(12-40-42(36,37)38)6-24-14(2)22(18)32;;;;/h5-6,31-32H,3-4,7-12H2,1-2H3,(H,27,28)(H,29,30)(H2,33,34,35)(H2,36,37,38);;;;/q;+2;3*+1/p-5
SMILES Code
O=P(O[Na])(O[Na])OCC1=CN=C(C)C2=C1C[N@]3(C4)CC[N@@]56CC7=C(O([H])[Mn]35(OC4=O)(OC(C6)=O)O2[H])C(C)=NC=C7COP(O)(O[Na])=O
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 757.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Karlsson JOG, Jynge P, Ignarro LJ. May Mangafodipir or Other SOD Mimetics Contribute to Better Care in COVID-19 Patients? Antioxidants (Basel). 2020 Oct 10;9(10):971. doi: 10.3390/antiox9100971. PMID: 33050459; PMCID: PMC7601469. 2: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. Mangafodipir. 2018 Oct 31. PMID: 30000475. 3: Qin Y, Iwase A, Murase T, Bayasula, Ishida C, Kato N, Nakamura T, Osuka S, Takikawa S, Goto M, Kotani T, Kikkawa F. Protective effects of mangafodipir against chemotherapy-induced ovarian damage in mice. Reprod Biol Endocrinol. 2018 Oct 27;16(1):106. doi: 10.1186/s12958-018-0426-y. PMID: 30368246; PMCID: PMC6204278. 4: Sanchez-Ramos J, Song S, Kong X, Foroutan P, Martinez G, Dominguez-Viqueria W, Mohapatra S, Mohapatra S, Haraszti RA, Khvorova A, Aronin N, Sava V. Chitosan-Mangafodipir nanoparticles designed for intranasal delivery of siRNA and DNA to brain. J Drug Deliv Sci Technol. 2018 Feb;43:453-460. doi: 10.1016/j.jddst.2017.11.013. Epub 2017 Nov 21. PMID: 29805475; PMCID: PMC5967853. 5: Karlsson JOG, Andersson RG, Jynge P. Mangafodipir a Selective Cytoprotectant - with Special Reference to Oxaliplatin and Its Association to Chemotherapy- Induced Peripheral Neuropathy (CIPN). Transl Oncol. 2017 Aug;10(4):641-649. doi: 10.1016/j.tranon.2017.04.012. Epub 2017 Jun 29. PMID: 28668762; PMCID: PMC5496205. 6: Karlsson JE, El-Saadi W, Ali M, Puskar W, Skogvard P, Engvall JE, Andersson RG, Maret E, Jynge P. Mangafodipir as a cardioprotective adjunct to reperfusion therapy: a feasibility study in patients with ST-segment elevation myocardial infarction. Eur Heart J Cardiovasc Pharmacother. 2015 Jan;1(1):39-45. doi: 10.1093/ehjcvp/pvu021. PMID: 27533964. 7: Karlsson JO, Ignarro LJ, Lundström I, Jynge P, Almén T. Calmangafodipir [Ca4Mn(DPDP)5], mangafodipir (MnDPDP) and MnPLED with special reference to their SOD mimetic and therapeutic properties. Drug Discov Today. 2015 Apr;20(4):411-21. doi: 10.1016/j.drudis.2014.11.008. Epub 2014 Nov 20. PMID: 25463039. 8: Coriat R, Alexandre J, Nicco C, Quinquis L, Benoit E, Chéreau C, Lemaréchal H, Mir O, Borderie D, Tréluyer JM, Weill B, Coste J, Goldwasser F, Batteux F. Treatment of oxaliplatin-induced peripheral neuropathy by intravenous mangafodipir. J Clin Invest. 2014 Jan;124(1):262-72. doi: 10.1172/JCI68730. Epub 2013 Dec 20. PMID: 24355920; PMCID: PMC3871222. 9: Laskar A, Andersson RG, Li W. Fodipir and its dephosphorylated derivative dipyridoxyl ethyldiamine are involved in mangafodipir-mediated cytoprotection against 7β-hydroxycholesterol-induced cell death. Pharmacology. 2013;92(3-4):182-6. doi: 10.1159/000354601. Epub 2013 Sep 26. PMID: 24080534. 10: Karlsson JO, Kurz T, Flechsig S, Näsström J, Andersson RG. Superior therapeutic index of calmangafodipir in comparison to mangafodipir as a chemotherapy adjunct. Transl Oncol. 2012 Dec;5(6):492-502. doi: 10.1593/tlo.12238. Epub 2012 Dec 1. PMID: 23323161; PMCID: PMC3542842. 11: Ben Mosbah I, Mouchel Y, Pajaud J, Ribault C, Lucas C, Laurent A, Boudjema K, Morel F, Corlu A, Compagnon P. Pretreatment with mangafodipir improves liver graft tolerance to ischemia/reperfusion injury in rat. PLoS One. 2012;7(11):e50235. doi: 10.1371/journal.pone.0050235. Epub 2012 Nov 30. PMID: 23226251; PMCID: PMC3511495. 12: Karlsson JO, Adolfsson K, Thelin B, Jynge P, Andersson RG, Falkmer UG. First clinical experience with the magnetic resonance imaging contrast agent and superoxide dismutase mimetic mangafodipir as an adjunct in cancer chemotherapy-a translational study. Transl Oncol. 2012 Feb;5(1):32-8. doi: 10.1593/tlo.11277. Epub 2012 Feb 1. PMID: 22348174; PMCID: PMC3281413. 13: Coriat R, Leconte M, Kavian N, Bedda S, Nicco C, Chereau C, Goulvestre C, Weill B, Laurent A, Batteux F. Mangafodipir protects against hepatic ischemia- reperfusion injury in mice. PLoS One. 2011;6(11):e27005. doi: 10.1371/journal.pone.0027005. Epub 2011 Nov 2. PMID: 22073237; PMCID: PMC3206884. 14: Maurea S, Mollica C, Imbriaco M, Fusari M, Camera L, Salvatore M. Magnetic resonance cholangiography with mangafodipir trisodium in Caroli's disease with pancreas involvement. JOP. 2010 Sep 6;11(5):460-3. PMID: 20818116. 15: Laskar A, Miah S, Andersson RG, Li W. Prevention of 7β-hydroxycholesterol- induced cell death by mangafodipir is mediated through lysosomal and mitochondrial pathways. Eur J Pharmacol. 2010 Aug 25;640(1-3):124-8. doi: 10.1016/j.ejphar.2010.04.046. Epub 2010 May 7. PMID: 20452343. 16: Hirt D, Richardet JP, Urien S, Poupon J, Sogni P, Batteux F, Laurent A, Pavlovic S, Debray M, Treluyer JM, Weill B. Pharmacokinetic-pharmacodynamic modeling of manganese after a single intravenous infusion of mangafodipir in patients with acute alcoholic hepatitis. Ther Drug Monit. 2009 Oct;31(5):557-65. doi: 10.1097/FTD.0b013e3181affd6d. PMID: 19834427. 17: Boraschi P, Donati F, Gigoni R, Salemi S, Faggioni L, Del Chiaro M, Boggi U, Bartolozzi C, Falaschi F. Secretin-stimulated multi-detector CT versus mangafodipir trisodium-enhanced MR imaging plus MRCP in characterization of non- metastatic solid pancreatic lesions. Dig Liver Dis. 2009 Nov;41(11):829-37. doi: 10.1016/j.dld.2009.02.005. Epub 2009 Mar 20. PMID: 19303825. 18: Yri OE, Vig J, Hegstad E, Hovde O, Pignon I, Jynge P. Mangafodipir as a cytoprotective adjunct to chemotherapy--a case report. Acta Oncol. 2009;48(4):633-5. doi: 10.1080/02841860802680427. PMID: 19169914. 19: Kim JH, Kim MJ, Park YN, Lee JT, Kim BR, Chung JB, Choi JS, Kim KS, Kim KW. Mangafodipir trisodium-enhanced MRI of hepatocellular carcinoma: correlation with histological characteristics. Clin Radiol. 2008 Nov;63(11):1195-204. doi: 10.1016/j.crad.2008.04.018. Epub 2008 Aug 8. PMID: 18929037. 20: De Filippo M, Bocchi C, Quartieri L, Corradi D, Zompatori M. Mangafodipir- DPDP enhanced MRI visualization of a pancreatic adenocarcinoma previously undetected by extracellular contrast enhanced CT and MRI. Acta Biomed. 2007 Dec;78(3):225-8. PMID: 18330084.

View History

UF-010

UF-010

New Featured